EveryONE Medicines and Mendelian Partner to Enable Personalized Therapies in the UK

Rare Daily Staff

EveryONE Medicines has entered into a strategic partnership with Mendelian to enable patients in the United Kingdom to have access to innovative personalized treatments.

EveryONE Medicines is developing a scalable, global framework to design, develop, and manufacture individualized medicines for children with life-threatening neurodegenerative diseases. The UK-based Mendelian uses its AI platform to perform large-scale analysis of electronic health records to identify people who may have an undiagnosed rare disease.

The collaboration will leverage Mendelian’s platform to analyze patient data within the UK’s healthcare system and identify individuals who may benefit from EveryONE Medicines’ treatment approaches for rare diseases.

The two companies said the collaboration will generate insights and deliver practical solutions that drive systemic change within the UK’s National Health Service to transform the patient journey from symptom onset to treatment access.

Personalized medicine represents a revolutionary shift from a one-size-fits-all approach to healthcare, instead tailoring treatments to an individual’s unique genetic makeup. This has the potential to unlock effective treatments for rare conditions, offering renewed hope to patients who traditional medical approaches have long underserved.

“Our collaboration with Mendelian is crucial for establishing the necessary groundwork in the U.K.,” said Kent Rogers, CEO at EveryONE Medicines. “By focusing on systemic change and addressing barriers to access, we can ensure that our personalized treatments reach the patients who need them, without unnecessary delays.”

The collaboration will work to identify people with ultra-rare diseases in the United Kingdom and ensure that the healthcare system is prepared to provide them with advanced personalized care.

As part of these efforts, the partners said they will work to understand the current U.K. healthcare landscape and map patient journeys there along with the cost and caregiver burden. They will develop and implement a patient-focused care pathway that aligns with the NHS Rare Disease Action Plan, and generate evidence to lay the groundwork for implementation of enhanced testing and personalized treatments.

“This collaboration will transform healthcare, allowing the incredible potential of individualized precision therapeutics to be realized. The UK and the NHS can lead the world in this innovative endeavor, making a profound difference by providing patients with life-changing care precisely when they need it,” said Peter Fish, CEO at Mendelian. “By working to understand the current challenges in the system and address them, we can pave the way for seamless integration of individualized treatments into the NHS.”

Photo: Kent Rogers, CEO at EveryONE Medicines